Key result
Prompt drug cessation, platelets, and DAPT restart resolve acute abciximab-induced thrombocytopenia.
Why the study?
Thrombocytopenia is a rare complication of glycoprotein IIb/IIIa inhibitor treatment requiring appropriate management strategies.
Case Report (n=1)
Alerts clinicians to platelet monitoring with abciximab; leaves open optimal prevention in clopidogrel-naive PCI patients.
Thrombocytopenia is a rare complication of glycoprotein IIb/IIIa treatment. We report a case of an acute profound abciximab induced thrombocytopenia and its successful management. The patient, presenting with unstable angina, underwent percutaneous coronary intervention with implantation of three drug eluting stents without receiving a clopidogrel loading dose according to guidelines. The rapid drop in the platelet count after abciximab elastomeric pump infusion was treated with drug discontinuation and platelet transfusion. The high risk of stent thrombosis was avoided by a timely readministration of the dual antiplatelet treatment.
No takes yet. Share an insight, caveat, or question.
Tanzilli et al. (2009) conducted a case report in Unstable angina (n=1). Abciximab was evaluated on Development and management of acute profound thrombocytopenia. Acute profound abciximab-induced thrombocytopenia in a patient undergoing PCI was successfully managed with drug discontinuation, platelet transfusion, and readministration of DAPT.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: